Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals focuses on developing and commercializing GI products. It markets linaclotide for irritable bowel syndrome with constipation or chronic idiopathic constipation under LINZESS or CONSTELLA names. The company also develops IW-3300, Apraglutide, and CNP-104 for various conditions. Strategic partnerships exist with AbbVie, AstraZeneca, and Astellas Pharma for linaclotide development and commercialization. Ironwood Pharmaceuticals was formerly Microbia, Inc., changing its name in 2008. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital and an asset-light, cash-generative model.
- Return on invested capital has stayed above 15% in each of the last 6 years (latest 37.8%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 37.8% against a cost of capital (WACC) of 6.1%, a spread of 31.7 percentage points.
- Asset-light, cash-generative model: capital expenditure takes only 0.1% of revenue and free cash flow was positive in each of the last 6 years.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/FCF 5.2x vs. a median of 21.4x and EV/EBITDA 8.3x vs. a median of 12.9x.
- EBITDA margin of 42.2% beats 93% of its 55 Drug Manufacturers - Specialty & Generic peers (median 22.4%).
Weaknesses
- High leverage: net debt is 3.1x EBITDA, against a median of 1.4x for its Drug Manufacturers - Specialty & Generic peers.
- Our discounted cash flow target price (2.99 USD) is 26% below the current price.
Key Financial Data